Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CFTR gene. The 3272–26A>G and 3849+10kbC>T CFTR mutations alter the correct splicing of the CFTR gene, generating new acceptor and donor splice sites respectively. Here we develop a genome editing approach to permanently correct these genetic defects, using a single crRNA and the Acidaminococcus sp. BV3L6, AsCas12a. This genetic repair strategy is highly precise, showing very strong discrimination between the wild-type and mutant sequence and a complete absence of detectable off-targets. The efficacy of this gene correction strategy is verified in intestinal organoids and airway epithelial cells derived from CF patients carrying the 3272–26A>G or 3849+10kbC>T mutations, showing efficient repair and complete functional recovery of the CFTR channel. These results demonstrate that allele-specific genome editing with AsCas12a can correct aberrant CFTR splicing mutations, paving the way for a permanent splicing correction in genetic diseases. Cystic fibrosis is caused by mutations in the CFTR chloride channel. Here, the authors develop a gene therapy approach using the programmable nuclease AsCas12a to correct a splicing mutation in CFTR, and show efficient repair of the mutation and recovery of CFTR function in patient-derived organoids and airway epithelial cells.

[1]  Jin-Soo Kim,et al.  Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells , 2016, Nature Biotechnology.

[2]  Karl Deisseroth,et al.  Corrigendum: Ventral hippocampal afferents to the nucleus accumbens regulate susceptibility to depression , 2015, Nature Communications.

[3]  L. Zentilin,et al.  VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9 , 2018, Molecular therapy. Nucleic acids.

[4]  S. Birket,et al.  Roadmap for an early gene therapy for cystic fibrosis airway disease , 2017, Prenatal diagnosis.

[5]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[6]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.

[7]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA , 1989, Science.

[8]  N. Gray,et al.  Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors , 2017, Nature Communications.

[9]  Y. Kong,et al.  Correction of F508del CFTR in airway epithelium using nanoparticles delivering triplex-forming PNAs , 2015, Nature communications.

[10]  V. Baekelandt,et al.  Immunological ignorance allows long-term gene expression after perinatal recombinant adeno-associated virus-mediated gene transfer to murine airways. , 2014, Human gene therapy.

[11]  X. Estivill,et al.  Cystic fibrosis patients with the 3272-26A>G splicing mutation have milder disease than F508del homozygotes: a large European study , 2001, Journal of medical genetics.

[12]  Y. Kong,et al.  Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium , 2015, Nature Communications.

[13]  Hans Clevers,et al.  Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. , 2011, Gastroenterology.

[14]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[15]  Feng Zhang,et al.  Engineered Cpf1 variants with altered PAM specificities increase genome targeting range , 2017, Nature Biotechnology.

[16]  Nick Barker,et al.  Organoids as an in vitro model of human development and disease , 2016, Nature Cell Biology.

[17]  Charlie Huveneers,et al.  How Close is too Close? The Effect of a Non-Lethal Electric Shark Deterrent on White Shark Behaviour , 2016, PloS one.

[18]  Thomas Ferkol,et al.  Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. , 2007, Human gene therapy.

[19]  A. Cereseto,et al.  Reduction of HIV-1 Infectivity through Endoplasmic Reticulum-Associated Degradation-Mediated Env Depletion , 2014, Journal of Virology.

[20]  Christopher B. Burge,et al.  Maximum Entropy Modeling of Short Sequence Motifs with Applications to RNA Splicing Signals , 2004, J. Comput. Biol..

[21]  David K. Gifford,et al.  Predictable and precise template-free CRISPR editing of pathogenic variants , 2018, Nature.

[22]  F. Pagani,et al.  An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects , 2012, Human molecular genetics.

[23]  Meagan E. Sullender,et al.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.

[24]  Hans Clevers,et al.  A functional CFTR assay using primary cystic fibrosis intestinal organoids , 2013, Nature Medicine.

[25]  B. Kerem,et al.  Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. , 2000, Human molecular genetics.

[26]  P. Harrison,et al.  Cas9/gRNA targeted excision of cystic fibrosis-causing deep-intronic splicing mutations restores normal splicing of CFTR mRNA , 2017, PloS one.

[27]  Hans Clevers,et al.  Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.

[28]  M. S. Chapman,et al.  An essential receptor for adeno-associated virus infection , 2015, Nature.

[29]  Sleiman Razzouk,et al.  CRISPR‐Cas9: A cornerstone for the evolution of precision medicine , 2018, Annals of human genetics.

[30]  M. Garcia-Blanco,et al.  5' exon replacement and repair by spliceosome-mediated RNA trans-splicing. , 2003, RNA.

[31]  Francesca Baglio,et al.  Comparing resting state fMRI de-noising approaches using multi- and single-echo acquisitions , 2017, PloS one.

[32]  A. Doherty,et al.  Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis , 2016, Thorax.

[33]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[34]  J. Davies,et al.  Genetic medicines for CF: Hype versus reality , 2016, Pediatric pulmonology.

[35]  Antoine M. van Oijen,et al.  Real-time single-molecule observation of rolling-circle DNA replication , 2009, Nucleic acids research.

[36]  E. Buratti,et al.  SR protein-mediated inhibition of CFTR exon 9 inclusion: molecular characterization of the intronic splicing silencer , 2007, Nucleic acids research.

[37]  Jinglan Zhou,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[38]  A. López-Requena,et al.  Engineered tobacco etch virus (TEV) protease active in the secretory pathway of mammalian cells. , 2015, Journal of biotechnology.

[39]  R. Crystal,et al.  Genetic Modification of the Lung Directed Toward Treatment of Human Disease. , 2017, Human gene therapy.

[40]  M. Knowles,et al.  Correction of Aberrant Splicing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene by Antisense Oligonucleotides* , 1999, The Journal of Biological Chemistry.

[41]  C. von Kalle,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.

[42]  D. C. Swarts,et al.  Cas9 versus Cas12a/Cpf1: Structure–function comparisons and implications for genome editing , 2018, Wiley interdisciplinary reviews. RNA.

[43]  M. van der Burg,et al.  Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells , 2014, Nature.

[44]  F. Demichelis,et al.  Hit and go CAS9 delivered through a lentiviral based self-limiting circuit , 2017, Nature Communications.

[45]  T. Blumenthal,et al.  Trans‐splicing , 2011, Wiley interdisciplinary reviews. RNA.

[46]  V. Baekelandt,et al.  rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice. , 2016, American journal of respiratory and critical care medicine.

[47]  Johan Hofkens,et al.  Super-resolution optical DNA Mapping via DNA methyltransferase-directed click chemistry , 2014, Nucleic acids research.

[48]  Martin J. Aryee,et al.  Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells , 2016, Nature Biotechnology.

[49]  M. Rubin,et al.  Inherited determinants of early recurrent somatic mutations in prostate cancer , 2017, Nature Communications.

[50]  R. Ravazzolo,et al.  Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia. , 2018, Cell chemical biology.

[51]  Richard L. Frock,et al.  Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases , 2014, Nature Biotechnology.

[52]  H. Clevers,et al.  Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis , 2016, Science Translational Medicine.

[53]  P. McCray,et al.  Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease , 2019, Genes.

[54]  T. Cooper Use of minigene systems to dissect alternative splicing elements. , 2005, Methods.

[55]  Garry R. Cutting,et al.  Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.

[56]  J C Olsen,et al.  A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. , 1994, The New England journal of medicine.

[57]  Seng H. Cheng,et al.  Organizing Section: Biochemistry/Molecular Biology Program Number: 4468 Poster Board Number: B0123 Presentation Time: 11:00 AM–12:45 PM CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10 , 2017 .

[58]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[59]  J. Puck,et al.  Lentiviral Gene Therapy Combined with Low‐Dose Busulfan in Infants with SCID‐X1 , 2019, The New England journal of medicine.

[60]  E. M. DeGennaro,et al.  Multiplex gene editing by CRISPR-Cpf1 through autonomous processing of a single crRNA array , 2016, Nature Biotechnology.

[61]  M. Amaral,et al.  Cystic fibrosis patients with the 3272‐26A→G mutation have mild disease, leaky alternative mRNA splicing, and CFTR protein at the cell membrane , 1999, Human mutation.

[62]  M. de Braekeleer,et al.  The CFTR 3849+10kbC->T and 2789+5G->A alleles are associated with a mild CF phenotype , 2005, European Respiratory Journal.

[63]  E. Caci,et al.  In vitro Methods for the Development and Analysis of Human Primary Airway Epithelia , 2018, Front. Pharmacol..

[64]  C. von Kalle,et al.  Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation in vivo. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[65]  Alessandro Romanel,et al.  A highly specific SpCas9 variant is identified by in vivo screening in yeast , 2018, Nature Biotechnology.

[66]  Gaurav Sahay,et al.  Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  Mauro Giacca,et al.  Virus-mediated gene delivery for human gene therapy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[68]  A. May,et al.  DNA Repair Profiling Reveals Nonrandom Outcomes at Cas9-Mediated Breaks. , 2016, Molecular cell.

[69]  Nikhil T. Awatade,et al.  Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine , 2018, Front. Pharmacol..

[70]  Steve Cunningham,et al.  Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial , 2015 .

[71]  C. Higgins,et al.  Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor1α promoter , 2001, Gene Therapy.

[72]  Nicholas A. Rossi,et al.  Inference of CRISPR Edits from Sanger Trace Data , 2019, bioRxiv.

[73]  R. Cimaz,et al.  Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis , 2019, Front. Pharmacol..

[74]  T. Cathomen,et al.  Targeted Integration of a Super-Exon into the CFTR Locus Leads to Functional Correction of a Cystic Fibrosis Cell Line Model , 2016, PloS one.

[75]  Matthew C. Canver,et al.  Analyzing CRISPR genome-editing experiments with CRISPResso , 2016, Nature Biotechnology.

[76]  Jennifer A. Doudna,et al.  CRISPR-Cas guides the future of genetic engineering , 2018, Science.

[77]  Martin J. Aryee,et al.  GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases , 2014, Nature Biotechnology.

[78]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[79]  J. Manley,et al.  hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. , 2007, Human molecular genetics.

[80]  Multiplex gene editing by CRISPR-Cpf1 through autonomous processing of a single crRNA array , 2016 .